NasdaqGS:SRDX

Stock Analysis Report

Executive Summary

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential.

Share Price & News

How has Surmodics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

5.4%

NasdaqGS:SRDX

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

-40.9%

NasdaqGS:SRDX

9.7%

US Medical Equipment

1.9%

US Market

SRDX underperformed the Medical Equipment industry which returned 9.6% over the past year.

SRDX underperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

SRDXIndustryMarket
7 Day5.4%1.5%0.8%
30 Day4.8%0.7%3.4%
90 Day7.6%2.4%2.1%
1 Year-40.9%-40.9%10.6%9.7%4.2%1.9%
3 Year63.7%63.7%70.2%65.0%46.7%37.2%
5 Year155.1%155.1%136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is Surmodics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Surmodics undervalued based on future cash flows and its price relative to the stock market?

25%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Surmodics's share price is below the future cash flow value, and at a moderate discount (> 20%).

Surmodics's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Surmodics is overvalued based on earnings compared to the US Medical Equipment industry average.

Surmodics is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Surmodics is poor value based on expected growth next year.


Price Based on Value of Assets

Surmodics is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Surmodics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

20.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Surmodics's revenue is expected to grow by 11.2% yearly, however this is not considered high growth (20% yearly).

Surmodics's earnings are expected to grow significantly at over 20% yearly.

Surmodics's revenue growth is expected to exceed the United States of America market average.

Surmodics's earnings growth is expected to exceed the United States of America market average.

Surmodics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Surmodics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has Surmodics performed over the past 5 years?

-47.3%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Surmodics's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.

Surmodics has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Surmodics has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.


Return on Equity

Surmodics has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Surmodics used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Surmodics's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Surmodics's financial position?


Financial Position Analysis

Surmodics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Surmodics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Surmodics has no debt.

Surmodics has not taken on any debt in the past 5 years.

Surmodics has no debt, it does not need to be covered by operating cash flow.

Surmodics has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Surmodics has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Surmodics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Surmodics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Surmodics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Surmodics has not reported any payouts.

Unable to verify if Surmodics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Surmodics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Surmodics's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average management tenure


CEO

Gary Maharaj (56yo)

8.8yrs

Tenure

US$2,402,237

Compensation

Mr. Gary R. Maharaj has been the Chief Executive Officer and President at Surmodics, Inc. since December 27, 2010. Mr. Maharaj served as the Chief Executive Officer and President at Arizant Inc. from 2006  ...


CEO Compensation Analysis

Gary's remuneration is about average for companies of similar size in United States of America.

Gary's compensation has increased in line with Surmodics recently becoming profitable.


Management Age and Tenure

3.8yrs

Average Tenure

53yo

Average Age

The tenure for the Surmodics management team is about average.


Board Age and Tenure

5.6yrs

Average Tenure

63yo

Average Age

The tenure for the Surmodics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$147,40827 Feb 19
Lisa Heine
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,569
Max PriceUS$57.38

Ownership Breakdown


Management Team

  • Charlie Olson (55yo)

    Senior Vice President of Commercial & Business Development - Medical Devices

    • Tenure: 14.9yrs
    • Compensation: US$903.23k
  • Gregg Sutton (59yo)

    Vice President of Research & Development - Medical Devices

    • Tenure: 3.7yrs
    • Compensation: US$864.91k
  • Gary Maharaj (56yo)

    CEO, President & Director

    • Tenure: 8.8yrs
    • Compensation: US$2.40m
  • Bryan Phillips (48yo)

    Senior VP of Legal

    • Tenure: 11yrs
    • Compensation: US$962.94k
  • Joe Stich (54yo)

    VP & GM of In-Vitro Diagnostics

    • Tenure: 8.1yrs
    • Compensation: US$696.13k
  • Tim Arens (52yo)

    Chief Financial Officer

    • Tenure: 1.3yrs
    • Compensation: US$798.63k
  • Tom Greaney (53yo)

    Chief Operating Officer of Medical Devices

    • Tenure: 3.8yrs
    • Compensation: US$971.90k
  • John Manders (38yo)

    Corporate Controller & Principal Accounting Officer

    • Tenure: 1.3yrs
  • Teryl L. Sides (50yo)

    Senior VP & Chief Marketing Officer

    • Tenure: 0.8yrs

Board Members

  • Shawn McCormick (55yo)

    Independent Director

    • Tenure: 3.8yrs
    • Compensation: US$145.50k
  • Ron Kalich (72yo)

    Independent Director

    • Tenure: 5.6yrs
    • Compensation: US$156.00k
  • David Dantzker (76yo)

    Independent Director

    • Tenure: 8.7yrs
    • Compensation: US$151.00k
  • Sue Knight (65yo)

    Chairman of The Board

    • Tenure: 4.7yrs
    • Compensation: US$219.00k
  • José Bedoya (63yo)

    Independent Director

    • Tenure: 17.7yrs
    • Compensation: US$148.00k
  • Gary Maharaj (56yo)

    CEO, President & Director

    • Tenure: 8.8yrs
    • Compensation: US$2.40m
  • Lisa Heine (55yo)

    Director

    • Tenure: 2.4yrs
    • Compensation: US$144.00k

Company Information

Surmodics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Surmodics, Inc.
  • Ticker: SRDX
  • Exchange: NasdaqGS
  • Founded: 1979
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$629.741m
  • Shares outstanding: 13.49m
  • Website: https://www.surmodics.com

Number of Employees


Location

  • Surmodics, Inc.
  • 9924 West 74th Street
  • Eden Prairie
  • Minnesota
  • 55344
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SRDXNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDMar 1998
SU6DB (Deutsche Boerse AG)YesCommon StockDEEURMar 1998

Biography

Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates thro ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/17 23:42
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/09/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.